Shares of Icosavax, Inc. (NASDAQ: ICVX) rose sharply in pre-market trading after AstraZeneca announced plans to buy Icosavax in a deal valued at up to $1.1 billion.
Icosavax also reported topline interim Phase 2 results for combination VLP vaccine candidate IVX-A12 against RSV and hMPV in older adults.
Icosavax shares gained 44.8% to $15.19 in pre-market trading.
Here are some other stocks moving in pre-market trading.
Gainers
- Bruush Oral Care Inc. (NASDAQ: BRSH) shares rose 76.8% to $0.2882 in pre-market trading after gaining over 5% on Monday.
- Connect Biopharma Holdings Limited (NASDAQ: CNTB) rose 32.2% to $1.19 in pre-market trading. Connect Biopharma will present top-line data from the global Phase 2b trial evaluating rademikibart’s efficacy and safety in patients with moderate-to-severe asthma on Dec. 12, 2023.
- Kaival Brands Innovations Group, Inc. (NASDAQ: KAVL) shares rose 28% to $0.3159 in pre-market trading. Kaival Brands recently appointed James W. Dobbins as General Counsel.
- IN8bio, Inc.(NASDAQ: INAB) gained ...